Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
PXekgXm0f1etuaxY